Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
基本信息
- 批准号:9797712
- 负责人:
- 金额:$ 41.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-24 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AGFG1 geneAbbreviationsAddressAntigen PresentationAntigen Presentation PathwayAntigen-Presenting CellsAntigensBackBindingBiologicalCD8-Positive T-LymphocytesCellsCleaved cellComplexCross PresentationCytosolDataDendritic CellsDevelopmentDiseaseDoxycyclineEnvironmentFaceGenerationsGeneticGoalsGrantHealthHybridsI-antigenImmune responseImmune systemImmunityImmunologic MonitoringImmunologic SurveillanceImmunotherapyIngestionKnock-outLeadLinkMajor Histocompatibility ComplexMalignant NeoplasmsModelingMonitorNucleoproteinsOligopeptidesOvalbuminPA700 proteasome activatorPathologic ProcessesPathway interactionsPatientsPeptide TransportPeptidesPhagosomesPhysiologicalPolyubiquitinProcessProteasome BindingProteinsProteomicsRoleSubunit VaccinesT cell responseTertiary Protein StructureTestingTissuesUbiquitinVaccinesVacuoleViralVirusVirus Diseasesbasebeta-2 Microglobulinin vivoinsightmacrophagemulticatalytic endopeptidase complexpathogenpeptide Ipreventresponsevaccine developmentvaccine immunotherapy
项目摘要
Abstract
In most cells the MHC I antigen presentation pathway exclusively displays peptides that are derived from a cell's
own proteins. In contrast, dendritic cells (DCs) and macrophages (MØs) are capable of acquiring and then
displaying peptides from external antigens through a process called cross presentation (XPT). XPT is the key
mechanism that allows the immune system to recognize and then mobilize a CD8 T cell response to cancers,
many viral infections and intracellular pathogens. Consequently, this pathway is important for immune
surveillance and is an attractive target to enable vaccines to elicit CD8 T cell immunity, which is something
current subunit vaccines fail to do. The overall goal of this grant is to elucidate key mechanisms that allow DCs
to carry out this critical function. In the major XPT pathway, exogenous proteins are first internalized into
phagosomes and then transferred into the cytosol, where they are cleaved into oligopeptides by proteasomes.
Recent data suggests that the proteasome-generated peptides for XPT are subsequently imported back into
phagosomes for binding to MHC I molecules (referred to here as “phagosomal XPT”). However, why such
peptides would not simply be delivered to MHC I molecules in the ER, as most cytosolic generated peptides are,
is a mystery and one that our first aim seeks to solve. Our underlying hypothesis, supported by preliminary data,
is that a subset of proteasomes physically associates with the cytosolic face of phagosomes and does so by via
their PA28 capping complex binding to the cytosolic domains of the peptide-loading complex (TAP+Tapasin).
This arrangement thereby links local peptide generation (by the phagosome-bound proteasomes) to local peptide
transport (by phagosomal TAP). The importance of these hypotheses is that they have the potential to fill in key
missing links in the phagosomal XPT pathway and to identify an important function for PA28 complexes, which
up until now have thought to be relatively unimportant. Our second aim seeks to elucidate mechanisms that allow
MHC I molecules to bind peptides in the “unfriendly” environment of the phagosome and to address the question
of why XPT of antigens is surprisingly much more efficient when the exogenous antigen is cell-associated, as
compared to the same antigen in any other form. This aim will test the hypothesis that ß2 microblobulin (ß2M)
from ingested exogenous cells promotes the formation of peptide-MHC I complexes in phagosomes. In this
mechanism, free ß2M (from ingested cells) + free MHC I heavy chains delivered to and/or generated in
phagosomes (from complexes denatured in the vacuole) + peptides (from PA28-proteasome-products that are
imported into phagosomes by TAP) associate to form intraphagosomal MHC I-peptide complexes. The
importance of this hypothesis is that it would provide insight into a biologically important process. Moreover, this
mechanism may be able to be manipulated to enhance XPT for vaccines/immunotherapies.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH L ROCK其他文献
KENNETH L ROCK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH L ROCK', 18)}}的其他基金
Novel histone-binding C-type lectin receptors and their role in sterile inflammation and tissue injury
新型组蛋白结合 C 型凝集素受体及其在无菌炎症和组织损伤中的作用
- 批准号:
10566947 - 财政年份:2022
- 资助金额:
$ 41.88万 - 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
- 批准号:
10204986 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
- 批准号:
10414938 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Role of IRF2 in cancer immune evasion and immunotherapy
IRF2在癌症免疫逃避和免疫治疗中的作用
- 批准号:
10667446 - 财政年份:2020
- 资助金额:
$ 41.88万 - 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
- 批准号:
10392945 - 财政年份:2019
- 资助金额:
$ 41.88万 - 项目类别:
Mechanisms of cross-presenting antigens in phagosomes on MHC I molecules to stimulate CD8 T lymphocyte responses
MHC I分子上的吞噬体中交叉呈递抗原刺激CD8 T淋巴细胞反应的机制
- 批准号:
10606598 - 财政年份:2019
- 资助金额:
$ 41.88万 - 项目类别:
Role of Clec2d-DAMP interactions in the pathophysiology of tissue injury and sepsis
Clec2d-DAMP 相互作用在组织损伤和脓毒症病理生理学中的作用
- 批准号:
10164709 - 财政年份:2017
- 资助金额:
$ 41.88万 - 项目类别:
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
Tspan5 在 MHC I 抗原呈递和癌症免疫逃避中的作用
- 批准号:
10210168 - 财政年份:2016
- 资助金额:
$ 41.88万 - 项目类别:
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
Tspan5 在 MHC I 抗原呈递和癌症免疫逃避中的作用
- 批准号:
10362713 - 财政年份:2016
- 资助金额:
$ 41.88万 - 项目类别:
Elucidation of the role of 2 novel cross presentation genes
阐明 2 个新型交叉表达基因的作用
- 批准号:
9883698 - 财政年份:2016
- 资助金额:
$ 41.88万 - 项目类别:
相似海外基金
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8077875 - 财政年份:2010
- 资助金额:
$ 41.88万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
7866149 - 财政年份:2010
- 资助金额:
$ 41.88万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8589822 - 财政年份:2010
- 资助金额:
$ 41.88万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8305149 - 财政年份:2010
- 资助金额:
$ 41.88万 - 项目类别: